Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.69+0.02 (+3.63%)
Close on Nov 17, 2026Market cap $41.86MP/E –Yield –
Aldeyra Therapeutics cash
Cash and short-term investments held at the end of each period.
Aldeyra Therapeutics's cash was $45.09M at Jun 30, 2026. For fiscal 2025 it was $70.04M, down 30.8% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $229.79M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.04M | -30.8% |
| FY2024 | Dec 31, 2024 | $101.15M | -29.2% |
| FY2023 | Dec 31, 2023 | $142.82M | -18.1% |
| FY2022 | Dec 31, 2022 | $174.30M | -24.1% |
| FY2021 | Dec 31, 2021 | $229.79M | +195.1% |
| FY2020 | Dec 31, 2020 | $77.86M | +75.3% |
| FY2019 | Dec 31, 2019 | $44.43M | -6.2% |
| FY2018 | Dec 31, 2018 | $47.36M | +136.5% |
| FY2017 | Dec 31, 2017 | $20.02M | -19.6% |
| FY2016 | Dec 31, 2016 | $24.90M | -9.8% |
| FY2015 | Dec 31, 2015 | $27.60M | +223.7% |
| FY2014 | Dec 31, 2014 | $8.53M | +161.4% |
| FY2013 | Dec 31, 2013 | $3.26M | +166.6% |
| FY2012 | Dec 31, 2012 | $1.22M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $45.09M | -45.0% |
| Q1 FY2026 | Mar 31, 2026 | $65.00M | -27.8% |
| Q4 FY2025 | Dec 31, 2025 | $70.04M | -30.8% |
| Q3 FY2025 | Sep 30, 2025 | $75.30M | -33.2% |
| Q2 FY2025 | Jun 30, 2025 | $81.92M | -31.9% |
| Q1 FY2025 | Mar 31, 2025 | $90.06M | -32.3% |
| Q4 FY2024 | Dec 31, 2024 | $101.15M | -29.2% |
| Q3 FY2024 | Sep 30, 2024 | $112.74M | -21.3% |
| Q2 FY2024 | Jun 30, 2024 | $120.33M | -20.7% |
| Q1 FY2024 | Mar 31, 2024 | $133.04M | -19.4% |
| Q4 FY2023 | Dec 31, 2023 | $142.82M | -18.1% |
| Q3 FY2023 | Sep 30, 2023 | $143.33M | -22.7% |
| Q2 FY2023 | Jun 30, 2023 | $151.68M | -22.9% |
| Q1 FY2023 | Mar 31, 2023 | $165.03M | -23.9% |
| Q4 FY2022 | Dec 31, 2022 | $174.30M | -24.1% |
| Q3 FY2022 | Sep 30, 2022 | $185.33M | -23.2% |
| Q2 FY2022 | Jun 30, 2022 | $196.69M | -21.2% |
| Q1 FY2022 | Mar 31, 2022 | $216.87M | +56.6% |
| Q4 FY2021 | Dec 31, 2021 | $229.79M | +195.1% |
| Q3 FY2021 | Sep 30, 2021 | $241.37M | +180.1% |
| Q2 FY2021 | Jun 30, 2021 | $249.74M | +311.5% |
| Q1 FY2021 | Mar 31, 2021 | $138.44M | +259.2% |
| Q4 FY2020 | Dec 31, 2020 | $77.86M | +75.3% |
| Q3 FY2020 | Sep 30, 2020 | $86.18M | +13.1% |
| Q2 FY2020 | Jun 30, 2020 | $60.69M | -12.6% |
| Q1 FY2020 | Mar 31, 2020 | $38.54M | -53.1% |
| Q4 FY2019 | Dec 31, 2019 | $44.43M | -6.2% |
| Q3 FY2019 | Sep 30, 2019 | $76.17M | +323.0% |
| Q2 FY2019 | Jun 30, 2019 | $69.46M | +182.3% |
| Q1 FY2019 | Mar 31, 2019 | $82.12M | +310.1% |
| Q4 FY2018 | Dec 31, 2018 | $47.36M | +43.1% |
| Q3 FY2018 | Sep 30, 2018 | $18.01M | +23.3% |
| Q2 FY2018 | Jun 30, 2018 | $24.61M | +27.5% |
| Q4 FY2017 | Dec 31, 2017 | $20.02M | -19.6% |
| Q3 FY2017 | Sep 30, 2017 | $33.10M | +127.2% |
| Q2 FY2017 | Jun 30, 2017 | $14.61M | -17.0% |
| Q1 FY2017 | Mar 31, 2017 | $19.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $24.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.57M | – |
| Q2 FY2016 | Jun 30, 2016 | $17.61M | – |
See a number that looks wrong?